Combined Tevatron upper limit on gg->H->W+W- and constraints on the Higgs boson mass in fourth-generation fermion models

Report number: FERMILAB-PUB-10-125-EWe combine results from searches by the CDF and D0 collaborations for a standard model Higgs boson (H) in the process gg->H->W+W- in p=pbar collisions at the Fermilab Tevatron Collider at sqrt{s}=1.96 TeV. With 4.8 fb-1 of integrated luminosity analyzed at CDF and 5.4 fb-1 at D0, the 95% Confidence Level upper limit on \sigma(gg->H) x B(H->W+W-) is 1.75 pb at m_H=120 GeV, 0.38 pb at m_H=165 GeV, and 0.83 pb at m_H=200 GeV. Assuming the presence of a fourth sequential generation of fermions with large masses, we exclude at the 95% Confidence Level a standard-model-like Higgs boson with a mass between 131 and 204 GeV.We combine results from searches by the CDF and D0 collaborations for a standard model Higgs boson (H) in the process gg→H→W+W- in pp̅ collisions at the Fermilab Tevatron Collider at √s=1.96  TeV. With 4.8  fb-1 of integrated luminosity analyzed at CDF and 5.4  fb-1 at D0, the 95% confidence level upper limit on σ(gg→H)×B(H→W+W-) is 1.75 pb at mH=120  GeV, 0.38 pb at mH=165  GeV, and 0.83 pb at mH=200  GeV. Assuming the presence of a fourth sequential generation of fermions with large masses, we exclude at the 95% confidence level a standard-model-like Higgs boson with a mass between 131 and 204 GeV.Peer reviewe

Measurement of the average time-integrated mixing probability of b-flavored hadrons produced at the Fermilab Tevatron

We have measured the number of like-sign (LS) and opposite-sign (OS) lepton pairs arising from double semileptonic decays of b and (b) over bar hadrons, pair produced at the Fermilab Tevatron collider. The data samples were collected with the Collider Detector at Fermilab during the 1992-1995 collider run by triggering on the existence of mumu or emu candidates in an event. The observed ratio of LS to OS dileptons leads to a measurement of the average time-integrated mixing probability of all produced b-flavored hadrons which decay weakly, (χ) over bar =0.152+/-0.007 (stat)+/-0.011 (syst), that is significantly larger than the world average (χ) over bar =0.118+/-0.005

Observation of the narrow state X(3872)-\u3e J/psi pi(+)pi(-) in (p)over-barp collisions at root s=1.96 TeV

We report the observation of a narrow state decaying into J/psipi(+)pi(-) and produced in 220 pb(-1) of (p) over barp collisions at roots=1.96 TeV in the CDF II experiment. We observe 730+/-90 decays. The mass is measured to be 3871.3+/-0.7(stat)+/-0.4(syst) MeV/c(2), with an observed width consistent with the detector resolution. This is in agreement with the recent observation by the Belle Collaboration of the X(3872) meson

Abstract P1-09-04: Taxanes in Metastatic Breast Cancer: Claims Analysis of Neutropenia, Infections, and CSF Costs

Abstract Background: The taxanes (paclitaxel {Taxol}, docetaxel {Taxotere}, and nab-paclitaxel {Abraxane}) are used in women with metastatic breast cancer (MBC). Clinical trials indicate that these drugs may differ in their toxicity profiles. Utilizing medical claims data, we evaluated the rates of neutropenia and infectious complications and costs of colony-stimulating factors (CSF) associated with taxane-based chemotherapy in MBC. Objective: To determine if differences exist in rates of neutropenia and infections in patients receiving taxane-based chemotherapy for MBC. Additionally, to compare costs associated with CSF use for neutropenia between the taxanes. Methods: Women with MBC were identified with ICD-9-CM codes and by their prior use of adjuvant chemotherapy regimens. Paid medical claims (source: Ingenix Consulting) from May 1, 2006 to April 30, 2009 were analyzed. Study groups were defined according to the first taxane administered. Demographic and taxane utilization data were collected. We accounted for differing dosing schedules by calculating cumulative taxane exposure (CTE) based on the mean number of doses received and mean days between doses. Taxane-related neutropenia or infection was defined as ICD-9-CM codes for these adverse events within 21 days of taxane administration. Cox proportional hazards models were used to compare rates between taxanes and adjusted for age, co-morbidity using the Romano index, and prior and concurrent chemo. Total CSF costs per patient with MBC were adjusted for a variety of variables with Tobit models. Results: 4,503 women (mean age: 53 +/− 10 years) with MBC were identified: 2,599 in the docetaxel group; 1,643 received paclitaxel; and 261 received nab-paclitaxel. On average, patients in the nab-paclitaxel group received more CTE (207.9 days) than either paclitaxel (110.2 days) or docetaxel (113.1 days). Compared with docetaxel users, women receiving nab-paclitaxel (HR 0.27; 95%CI 0.20-0.37) and paclitaxel (HR 0.63; 95%CI 0.56-0.71) were significantly less like to develop neutropenia. Nab-paclitaxel users also experienced lower rates of neutropenia compared with paclitaxel users (HR 0.43; 95% CI 0.31-0.60). Infectious complications were not different between the three drugs: nab-paclitaxel compared with docetaxel (HR 1.24; 95% CI 0.83-1.88), paclitaxel compared with docetaxel (HR 0.99; 95% CI 0.75-1.31), and nab-paclitaxel compared with paclitaxel (HR 1.26; 95% CI 0.83-1.90). Over the study period, the average nab-paclitaxel patient had 12,100 less in CSF costs compared with docetaxel (P&lt;0.001); patients receiving paclitaxel incurred 9,232 less in CSF costs than those receiving docetaxel (P&amp;lt;0.001). The difference between nab-paclitaxel and paclitaxel was also statistically significant (P&amp;lt;0.001). Conclusions: Compared with docetaxel and paclitaxel, patients receiving nab-paclitaxel had a higher cumulative taxane exposure, yet experienced a 73% and 57%, respectively, reduction in neutropenia rates. Patients receiving nab-paclitaxel spent significantly less on CSF than those receiving docetaxel or paclitaxel, but there was no difference in infectious complications. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-09-04.</jats:p

P1-10-03: Colony Stimulating Factor Use with Taxane-Based Therapy for Metastatic Breast Cancer: Claims Analysis of Prophylaxis, Treatment, and Costs.

Abstract Background: The taxanes (paclitaxel, docetaxel, and albumin-bound paclitaxel) are used in women with metastatic breast cancer (MBC). Clinical trials indicate that these drugs may differ in their toxicity profiles, including rates of neutropenia and need for colony stimulating factor (CSF) supportive therapy. Utilizing medical claims data, we evaluated prophylactic and treatment-related CSF use among women receive taxane-based chemotherapy regimens. Objective: To determine if differences exist in rates of CSF use for prophylaxis, treatment and associated costs in women receiving taxane-based chemotherapy for MBC. Methods: Women with MBC were identified with ICD-9-CM codes and by their prior use of adjuvant chemo regimens. Paid medical claims (source: Ingenix Consulting) from May 1, 2006 to April 30, 2009 were analyzed. Study groups were defined according to the first taxane administered. CSF utilization was classified as prophylaxis (0-5 days post-taxane administration), treatment (6-21 days post-taxane,) or non-taxane associated use (&amp;gt;21 days post-taxane). Comparisons were made between the taxane groups. All CSF costs were captured from date of first taxane to end of taxane therapy +21 days and categorized as above. Patients censored if ≥35 days elapsed with no taxane therapy. Two-stage regression analyses were performed. Control variables included age, Romano comorbidity score, and use of prior and other concurrent chemotherapy. Results: 4,503 women (mean age: 53 +/− 10 years) with MBC were identified: 2,599 in the docetaxel group; 1,643 received paclitaxel; and 261 received nab-paclitaxel. More patients receiving docetaxel received any CSF (75.6%) than either paclitaxel (49.8%) or albumin-bound paclitaxel (36.8% P&amp;lt;0.05 for each comparison). For docetaxel 70.5% of women received prophylactic CSF, whereas the rates were 47.0% for paclitaxel and 33.0 for albumin-bound paclitaxel (P&amp;lt;0.05). The rate of women receiving CSF in the albumin-bound paclitaxel group was not different than the other groups. Daily per-patient CSF expenditures during taxane therapy were $176.81 (95$168.20-$185.52) for docetaxel,$127.71(95% CI, $113.62-$142.60) for paclitaxel, and 46.24 (95% CI, $29.37-$67.25) for albumin-bound paclitaxel. Conclusions: Compared with docetaxel and paclitaxel, patients receiving albumin-bound paclitaxel had significantly lower prophylactic CSF use, yet did not experience any difference in treatment-related use. Daily per-patient CSF expenditures for albumin-bound paclitaxel were significantly lower than the other two taxanes. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-10-03.</jats:p